Originally Posted by Mulletsoldier
Both products are similar, insofar as animal models displaying increased cell-surface GLUT4 activity and GLUT4 gene promoter activity; an increase in MGU (muscle glucose uptake) and a decrease in plasma glucose levels; as well as inhibiting particular fat metabolic gene transcription factors, such PPAR∂. Despite these similarities, the key pathway that is differing between the two - the AMPk/p38-MAPK pathway - means they are going to have differing results in terms of the mitigation of fatigue, decrease in whole body adiposity, triglyceride and cholesterol synthesis, etc. In more basic terms, AP can be thought of more as a recomposition agent, whereas P-SLIN is for power, endurance, and muscle-belly fullness.